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Previewsengages the sympathetic nervous sys-
tem. Sympathetic enhancement causes
Ca2+ loading and Ca2+ release-channel
phosphorylation, both of which increase
EAD/DAD likelihood (Chen et al., 2014).
In addition, the associated greatly
increased metabolic demand challenges
mitochondrially deficient cells, causing
them to maximize anaerobic metabolism
with the production of large quantities of
toxic products typically seen with acute
myocardial ischemia (Carmeliet, 1999).
These toxic metabolites are free to diffuse
from the cell of origin and affect a sub-
stantial number of neighboring cells,
producing significant amplification and,
along with sympathetic enhancement,
creating a ‘‘perfect storm’’ for EAD/DAD
source generation.
In addition, mitochondrially deficient
cardiomyocytes in aged Twinkle mutant
mice could also contribute by lowering
the electrotonic load in the vicinity
of EAD/DAD-producing sources. Under
stress conditions, these cells likely lose
their capability to generate action poten-
tials and thus no longer constitute a
current sink to the EAD/DAD-producing
cell(s), decreasing the regional source-
sink mismatch. Given that electrotonic
influences extend up to 1 mm, it is
conceivable that a number of mitochond-
rially deficient myocytes could be found in
the neighborhood of an EAD/DAD-gener-ating source, reducing the electrical sink.
In this scenario, rare dysfunctional cells
might be understood conceptually as
‘‘centers of crystallization’’ for afterdepo-
larizations. In the absence of such ‘‘crys-
tallization centers,’’ a great majority of
emerging afterdepolarization ‘‘attempts’’
would be dampened by electrotonic ef-
fects of surrounding cells. Mitochondrially
deficient myocytes in the immediate sur-
rounding of ‘‘attemptor cells’’ may signifi-
cantly increase its chances to propagate
and precipitate an arrhythmic event.
Either way, one could conceive of the
sporadically distributed mitochondrially
deficient cells as ‘‘crystallization centers,’’
quiescent at rest but showing enhanced
disturbances under stress conditions
that alter their electrical properties and
affect their aged (and thus not completely
normal) neighbors in ways that generate
focal arrhythmias.
In conclusion, Baris et al. (2015)
have made an important contribution by
creating a mouse model of a previously
cryptic change in the aging human
heart—the appearance of sporadic mito-
chondrially deficient cells due to accu-
mulated mitochondrial DNA mutations.
They demonstrate that reproducing this
property of aging predisposes to stress-
induced cardiac rhythm disturbances.
More work is needed to understand the
detailed mechanisms and importance ofCell Metabolisthese electrical abnormalities, but these
observations and the availability of this
new model will contribute to solving the
important enigma of heart disease in the
elderly.REFERENCES
Baris, O.R., Ederer, S., Neuhaus, J.F.G., von Kleist-
Retzow, J.-C., Wunderlich, C.M., Pal, M., Wunder-
lich, F.T., Peeva, V., Zsurka, G., Kunz, W.S., et al.
(2015). Cell Met. 21, this issue, 667–677.
Carmeliet, E. (1999). Physiol. Rev. 79, 917–1017.
Chen, P.S., Chen, L.S., Fishbein, M.C., Lin, S.F.,
and Nattel, S. (2014). Circ Res. 114, 1500–1515.
Chow, G.V., Marine, J.E., Fleg, J.L., Lin, S.F., and
Nattel, S. (2012). Clin. Geriatr. Med. 28, 539–553.
Cooper, L.L., Li, W., Lu, Y., Centracchio, J., Teren-
tyeva, R., Koren, G., and Terentyev, D. (2013).
J. Physiol. 591, 5895–5911.
Khrapko, K., and Turnbull, D. (2014). Prog. Mol.
Biol. Transl. Sci. 127, 29–62.
Khrapko, K., Bodyak, N., Thilly, W.G., van Orsouw,
N.J., Zhang, X., Coller, H.A., Perls, T.T., Upton, M.,
Vijg, J., andWei, J.Y. (1999). Nucleic Acids Res. 27,
2434–2441.
Mu¨ller-Ho¨cker, J. (1989). Am. J. Pathol. 134, 1167–
1173.
Nattel, S., Andrade, J., Macle, L., Rivard, L., Dyrda,
K., Mondesert, B., and Khairy, P. (2014). Can. J.
Cardiol. 30 (Suppl ), S420–S430.
Wanagat, J., Cao, Z., Pathare, P., and Aiken, J.M.
(2001). FASEB J. 15, 322–332.Come to Where Insulin Resistance Is,
Come to AMPK CountryRube´n Nogueiras,1,2 Carlos Die´guez,1,2 and Miguel Lo´pez1,2,*
1Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigacio´n Sanitaria, Santiago de Compostela
15782, Spain
2CIBER Fisiopatologı´a de la Obesidad y Nutricio´n (CIBERobn), Santiago de Compostela 15706, Spain
*Correspondence: m.lopez@usc.es
http://dx.doi.org/10.1016/j.cmet.2015.04.021
The link between smoking and insulin resistance, despite weight loss, is well established; however, the
underlying mechanisms remain elusive. A recent article published in Nature Medicine by Wu et al. (2015)
reports that nicotine, the main bioactive component of tobacco smoke, activates AMPKa2 in adipocytes,
leading to impaired insulin sensitivity.The subjective experience of almost
every smoker is that tobacco affects
body weight, and indeed, smokers whotry to quit commonly suffer an increase
in body mass. This is often reported
as a ‘‘good reason’’ to keep smoking,which makes weight gain the main
cause of failure in smoking cessation
therapies (Filozof et al., 2004). It is wellm 21, May 5, 2015 ª2015 Elsevier Inc. 663
Figure 1. Schematic Representation of Nicotine Actions on White Adipose Tissue to Induce Insulin Resistance through AMPKa2
Nicotine binding to nicotinic acetylcholine receptor subunit a7 (AchRa7) augments ROS levels and increases phosphorylation of AMPKa2, which in turn
phosphorylates MAP kinase phosphatase-1 (MKP1), promoting its degradation. This causes impaired activation of p38 mitogen-activated protein kinase
(p38) and c-Jun N-terminal kinase (JNK), leading to dysfunction of insulin receptor substrate 1 (IRS1) and inhibition of AKT phosphorylation. This pathway
impairs insulin signaling and increases lipolysis.
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Previewsknown that nicotine, the main bioactive
component of tobacco, causes smok-
ing-induced changes in body weight.
Recent evidence has suggested that
nicotine acts in the CNS to induce
a catabolic state. Specifically, nicotine
activates proopiomelanocortin (POMC)
neurons in the arcuate nucleus of the hy-
pothalamus to decrease feeding (Mineur
et al., 2011) and inhibits AMP-activated
protein kinase (AMPK) in the ventrome-
dial nucleus of the hypothalamus to
increase brown adipose tissue (BAT)
thermogenesis through the sympathetic
nervous system (Martı´nez de Morentin
et al., 2012; Seoane-Collazo et al.,
2014), ultimately leading to weight loss.
Ironically, despite this reduction in
body weight, nicotine promotes insulin664 Cell Metabolism 21, May 5, 2015 ª2015resistance (IR) and hyperinsulinemia in
cigarette smokers and in individuals
consuming nicotine gum (Eliasson et al.,
1996). This is of relevance, as it implies
that the use of nicotine replacement ther-
apy during smoking cessation must be
temporary and controlled to avoid exac-
erbated IR in those subjects.
The mechanism by which smoking
and nicotine promote IR remains unclear.
In a recent paper published in Nature
Medicine, Yuan, Zou, and colleagues
provide new insights into this link
(Wu et al., 2015). Using in vitro assays,
mouse models, and also human adi-
pose tissue biopsies from non-smokers
and smokers, they show that nicotine,
acting through nicotinic acetylcholine
receptor subunit a7 (AchRa7), inducesElsevier Inc.elevation of ROS levels that activates
AMPKa2 in white adipose tissue (WAT),
which in turn phosphorylates MAP kinase
phosphatase-1 (MKP1), leading to its
degradation. Reduction of MKP1 causes
anomalous activation of both p38
mitogen-activated protein kinase (p38)
and c-Jun N-terminal kinase (JNK), lead-
ing to increased phosphorylation of
insulin receptor substrate 1 (IRS1) at
Ser307. This induces its degradation
and inhibition of AKT phosphorylation,
ultimately worsening insulin signaling
and upregulating lipolysis in WAT (Fig-
ure 1). As a consequence of the elevated
circulating free fatty acid (FFA) levels in
nicotine-treated mice, insulin sensitivity
is also impaired in skeletal muscle and
liver.
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PreviewsAs usual, when exciting data come
out, new questions are raised. Although
the link between nicotine and AMPKa2
in WAT adds new evidence about its
role in the regulation of lipolysis, some
questions remain unresolved. The
concept that FFAs mediate nicotine-
induced resistance is interesting, but
mostly based on experiments co-admin-
istering nicotine and acipimox (a chemi-
cal inhibitor of lipolysis). However,
acipimox administration is also linked to
other biological effects, such as an in-
crease of growth hormone (GH) secre-
tion, a hormone in itself able to decrease
insulin sensitivity (Cordido et al., 1996). It
is also likely that nicotine promotes
changes in adipokine secretion, such as
adiponectin, that could lead to impaired
insulin sensitivity. Therefore, systemic
measurement of such hormones could
offer a more comprehensive understand-
ing of the mechanism. Furthermore,
considering that nicotine induces IR in
WAT, an increase in macrophage infiltra-
tion and inflammation would be ex-
pected. However, recent data make
that possibility unlikely, since the acti-
vation of the AchRa7 by nicotine in
obese mouse models in fact enhances
insulin sensitivity via suppression of adi-
pose tissue inflammation and macro-
phage infiltration (Wang et al., 2011).
One possible explanation for those dis-
crepancies might be nicotine’s dosage
and the complexities of nicotine meta-
bolism. Current data have shown that
nicotine, when used at higher doses
(4 mg kg1 day1 in rats versus 1.5 mg
kg1 day1 in mice used in this study),
promotes an improvement in insulin
sensitivity in association with a catabolic
effect characterized by weight loss,
increased energy expenditure, lipid utili-
zation, locomotor activity, and elevated
BAT thermogenesis (Martı´nez de Moren-
tin et al., 2012; Seoane-Collazo et al.,
2014). Finally, alternative molecular path-ways may also be implicated in
liver and skeletal muscle. For example,
nicotine induces insulin resistance in
human skeletal muscle by activating
mammalian target of rapamycin (mTOR)
(Bergman et al., 2012), a hypothesis
that has not been addressed in the
current study, whereas no changes in
mTOR or its downstream targets were
found in WAT.
Although this investigation shows that
nicotine specifically activates AMPKa2 in
WAT, liver, and muscle, but not in hypo-
thalamus, the actions of nicotine on
AMPK are certainly complex. Previous re-
ports show that nicotine inhibits hypotha-
lamic AMPK, lacks effect in muscle, and
has a diet-dependent effect on AMPK in
liver (Martı´nez de Morentin et al., 2012;
Seoane-Collazo et al., 2014). The reasons
for this tissue-specific control are yet un-
clear and compromise the clinical poten-
tial that AMPK-targeting drugs may have
in smokers. Given that AMPKa2 is
required for nicotine-induced IR, it could
be concluded that global or specific inhi-
bition of this kinase in the WAT could
represent a new treatment for this disor-
der in smokers. However, the reality is
exactly the opposite: AMPK is a cellular
gauge involved in changes in energy sta-
tus (Kahn et al., 2005), and its activation
is one of the mechanisms for the widely
used antidiabetic drug metformin (Kahn
et al., 2005). Thus, AMPK inhibition for
the treatment of nicotine-induced IR
seems inconsistent because it could
worsen diabetes. Overall, this evidence,
besides the clear health benefits of stop-
ping smoking, raises some doubts about
the translation of this evidence to clinical
practice.
In summary, the study by Wu et al.
(2015) provides an important molecular
link between nicotine and the promotion
of IR through modulation of AMPKa2 in
WAT. It also offers new mechanistic evi-
dence about the deleterious effects ofCell Metabolisnicotine and the healthy benefits of smok-
ing cessation, which will be particularly
relevant in smokers suffering from type 2
diabetes. Taken together, these findings
further highlight that smoking and nicotine
gum are not the ideal strategies for weight
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